KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments-Reference-Cited by-同舟云学术

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments

Published:2021-05 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Koga Takamasa,Suda Kenichi,Fujino Toshio,Ohara Shuta,Hamada Akira,Nishino Masaya,Chiba Masato,Shimoji Masaki,Takemoto Toshiki,Arita Takeo,Gmachl Michael,Hofmann Marco H.,Soh Junichi,Mitsudomi Tetsuya

Funder

Japan Society for the Promotion of Science

Boehringer Ingelheim GmbH

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations;Capon;Nature,1983

2. RAS proteins and their regulators in human disease;Simanshu;Cell,2017

3. A comprehensive survey of Ras mutations in cancer;Prior;Cancer Res,2012

4. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer;Martin;J Thorac Oncol,2013

5. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation;Suda;Cancer Metastasis Rev,2010

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

2. Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins;Expert Opinion on Drug Discovery;2024-08-06

3. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance;Nature Cancer;2024-08-05

4. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?;Lung Cancer;2024-08

5. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer;Lung Cancer;2024-08